Precision Nutrition Counseling in Type 2 Diabetes Patients

Type 2 Diabetes Clinical Trial

Official title:

Development of Precision Nutrition Counseling in Type 2 Diabetes Patients: Using Continuous Glucose Monitoring System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04266171
• Other study ID #: H-1911-059-1078
• Status: Recruiting
• Phase: N/A
• Start date: January 16, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: January 2020
• Source: Seoul National University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effect of precision nutrition education using continuous glucose monitoring system (CGMS) in longterm glycemic control in patients with type 2 diabetes mellitus. Glucose levels in subjects who received diet education using CGMS will be compared to those in subjects who received conventional diet education.

Description:

Fifty subjects with type 2 diabetes will be recruited. Every subject will be randomized in two groups, which are CGMS education group and conventional education group. The study will be conducted for 12 weeks for each participants. Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data. Primary outcome is change of HbA1c from baseline for 12 weeks, and secondary outcomes are changes of fasting blood glucose level, body weight, waist circumference, blood lipid level, homeostatic model assessment of insulin resistance (HOMA-IR) , c-peptide, microbiome, 7-point self monitoring of blood glucose (SMBG), and compliance/satisfaction questionnaire from baseline for 12 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

• Type 2 diabetes patients (Fasting blood glucose = 126 mg/dl or HbA1c = 6.5% or Subjects who were previously diagnosed with type 2 diabetes and who have been treated with lifestyle modification only, oral anti-diabetic drugs or basal insulin)

• HbA1c 6.5%~10%

• Body weight change less than 5% in 3 month

• Subjects who agreed to the study protocol

Exclusion Criteria:

• Type 1 diabetes patients

• Subjects using insulin other than basal insulin

• Subjects who have newly started or have changed anti diabetic drugs within 3 months

• Subjects who have been received diabetes diet education within 6 months

• Females who are pregnant or doing breast feeding

• Subjects with alcohol addiction or drug abuse

• Subjects who are using drugs that can influence blood glucose levels (e.g. steroid)

• Subjects who are currently using acetaminophen or who should use acetaminophen during CGMS attach period

• Subjects who have skin problems on CGMS sensor insertion site (e.g. burn, excessive body hair, inflammation, rash, tattoo)

• Subjects who have newly started, changed, or stoped probiotics or prebiotics within 2 weeks

• Subjects who have used antibiotics (oral or intravenous) within 2 weeks

• In addition, if it falls under the exclusion criteria according to researchers discretion

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Behavioral:
• Diet education based on CGMS data
Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
• Conventional diet education
Control group will receive conventional diabetes diet education without CGMS data.

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Seoul National University Hospital	ChunLab

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in HbA1c from baseline		0 week, 12 weeks
Secondary	Change in fasting blood glucose level from baseline		0 week, 12 weeks
Secondary	Change in body weight from baseline		0 week, 12 weeks
Secondary	Change in waist circumference from baseline		0 week, 12 weeks
Secondary	Change in blood Triglyceride level from baseline		0 week, 12 weeks
Secondary	Change in blood High-density lipoprotein level from baseline		0 week, 12 weeks
Secondary	Change in blood Low-density lipoprotein level from baseline		0 week, 12 weeks
Secondary	Change in HOMA-IR from baseline		0 week, 12 weeks
Secondary	Change in c-peptide from baseline		0 week, 12 weeks
Secondary	Change in microbiome profile from baseline	Change in the diversity index of the gut microbiota, change in the compositions of the gut microbiota	0 week, 12 weeks
Secondary	Change in 7-point SMBG from baseline		0 week, 12 weeks
Secondary	Compliance/Satisfaction Questionnaire	Change in dietary habits, self-efficacy of diet management , and satisfaction with the education	0 week, 12 weeks